EurekaMag
+ Translate
+ Most Popular
Sobre os generos Lopadusa Stal e Bothrocoris Mayr (Hemiptera, Pentatomidae, Pentatomini)
RFEF pilot plant for inactivation of Escherichia coli in apple juice
Calpionella alpina Lorenz als "Leitfossil"
Sooretama: The Atlantic Rain Forest of Brazil. Francis Dov Por
Novel approaches in myeloma therapy
Preliminary Notes on the Study of Mitochondria During the 1st Stages of the Destruction of Cadavers
A preliminary study of the biology of lichee stink bug, Tessaratoma papulosa Drury, and its control
The status of the Sabu Island python - Die Situation des Savu-Pythons
Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. the UK Group for Immunoglobulin Replacement therapy in Multiple Myeloma
Conflicts between children
Clinical presentations in neuropsychiatry
Method of suturing a perforated ulcer of the stomach and duodenum
Identification of mechanical asphyxiation in cases of attempted masking of the homicide
Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of cell-free modified hemoglobin after exchange transfusion in rat and guinea pig
Is it warm? Is it real? Or just low spatial frequency?
Additions and corrections to the list of Korean Heteroptera
Factors contributing to the maintenance of oligotrophy in an alpine glacial moraine lake (Wallowa lake) in Northeast Oregon
Classification, paleoecology, and biostratigraphy of crinoids from the Stull Shale (Late Pennsylvanian) of Nebraska, Kansas, and Iowa
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Neue Formen der Bauchsammler aus Turkmenien (Hymenoptera, Apoidea)
Atypische Hühnerpest und Newcastle-Krankheit. Ein Identifizierungsversuch
Parasitellus fucorum in the debris of Apis mellifera - a risk of confusion with Tropilaelaps spp
Applying the Technology Acceptance Model to the introduction of healthcare information systems
Ein akarologischer Nachruf für den "Roland"
Mutation research on crop plants in Argentina

Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group


Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group



International Journal of Hematology 59(2): 113-123



ISSN/ISBN: 0925-5710

PMID: 8018904

From January 1988 until December 1990, 99 previously untreated patients with multiple myeloma (MM) were enrolled in a randomized prospective study comparing two combination chemotherapies with and without MCNU as induction therapy for MM; 49 patients with vindesine, melphalan and prednisolone (VMP therapy) versus 50 patients with MCNU, vindesine, melphalan and prednisolone (MCNU-VMP therapy). Seventy-two evaluable patients (34 patients in the VMP group, 38 in the MCNU-VMP group) were analyzed. The response rate was slightly higher with MCNU-VMP than with VMP (81.6% vs. 64.7%). In 43 responders (21 patients in the VMP group and 22 in the MCNU-VMP group) who were treated with the same regimen as the induction therapy to maintain remission, the remission duration was significantly longer in patients treated with MCNU-VMP than in those treated with VMP (median > 10.1 vs. 8.0 months, P = 0.018), particularly in patients with PS 3-4. The remission duration in the MCNU-VMP group was also slightly longer in the patients with stage III disease and who were older than 65 years. The median survival time showed no significant difference between the VMP group (20.3 months) and the MCNU-VMP group (> 15 months). Leukopenia, thrombocytopenia and nausea/vomiting were found to be somewhat severe in the MCNU-VMP group. In summary, MCNU-VMP therapy is effective as induction therapy for MM.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045566683

Download citation: RISBibTeXText

Related references

Combination chemotherapy of MCNU, melphalan, procarbazine, and prednisolone (MMPP) in multiple myeloma; disappearance of M-peak on serum electrophoretic pattern. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(4 Part 1): 863-865, 1989

MCNU-VMP therapy A new nitrosourea-based combination chemotherapy for multiple myeloma. British Journal of Haematology 93(Suppl 2): 302, 1996

Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(6): 2269-2273, 1989

Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301. International Journal of Hematology 79(2): 165-173, 2004

Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112. Japanese Journal of Clinical Oncology 41(4): 586-589, 2011

Report of phase I and II trials of melphalan, prednisolone, and thalidomide triplet combination therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplantation. International Journal of Hematology 110(4): 447-457, 2019

Combination chemotherapy of MCNU and interferon alfa-2a (genetical recombination) for advanced multiple myeloma. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(4 Part 1): 693-696, 1990

Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage IIi myeloma. the Nagoya Myeloma Cooperative Study Group. Japanese Journal of Cancer Research: Gann 81(12): 1320-1327, 1990

Vincristine cyclophosphamide melphalan prednisolone chemotherapy of multiple myeloma after ineffective melphalan prednisolone therapy. Blut 53(3): 227, 1986

Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Annals of Hematology 89(5): 489-497, 2010

Clinical study on the chemotherapy of multiple myeloma. 1. Therapeutic effect of sequential combination therapy using melphalan, ifosfamide, and prednisolone. Japanese Journal of Clinical Hematology 23(6): 847-853, 1982

Vindesine prednisolone therapy in chemotherapy refractory recurrent multiple myeloma. Onkologie 10(5): 279, 1987

Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase IIi study. Nordic Myeloma Study Group (NMSG). European Journal of Haematology 51(2): 80-85, 1993

Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma. Netherlands Journal of Medicine 27(2): 25-30, 1984

Prognostic factors in multiple myeloma treated with prednisolone and sequential melphalan and ifosfamide prednisolone and sequential melphalan and ifosfamide combination chemo therapy. Acta Medica Okayama 36(1): 39-48, 1982